JAK2 and acute lymphoblastic leukemia: The most important conclusion of this analysis is that RAS is active/inducible in 14/20 (70%) of primary DS-ALL samples analyzed, 8 of which had no RAS mutations, but 75% of those had either mutated or hyperphosphorylated JAK2 (Fig. 4c).